| Name: | Cloxacillin EP Impurity D |
| Catalogue No. | VL4390001 |
| CAS No. | 23598-72-3 |
| Molecular Formula | C11H8ClNO3 |
| Molecular Weight | 237.64 |
| Status | In-stock |
| IUPAC Name | 3-(2-Chlorophenyl)-5-methylisoxazole-4-carboxylic Acid |
| Synonyms | Cloxacillin related compound D |
| Appearance | Off White Powder |
| Description | Cloxacillin EP Impurity D (CAS No.: 23598-72-3) or Cloxacillin Related Compound D is a novel Pyrazole-Hydrazone derivative of Cloxacillin. Cloxacillin is used as initial therapy for presumed late-onset sepsis in the Neonatal Intensive Care Unit and also has an impact upon the outcome of coagulase-negative staphylococcal bacteremia. |
| References | Yang, Zaibo, et al. “Novel Pyrazole-Hydrazone Derivatives Containing an Isoxazole Moiety: Design, Synthesis, and Antiviral Activity.” Molecules, vol. 23, no. 7, July 2018, p. 1798,https://doi.org/10.3390/molecules23071798.Lawrence, Sarah L., et al. “Cloxacillin versus Vancomycin for Presumed Late-Onset Sepsis in the Neonatal Intensive Care Unit and the Impact upon Outcome of Coagulase Negative Staphylococcal Bacteremia: A Retrospective Cohort Study.” BMC Pediatrics, vol. 5, no. 1, Dec. 2005,htt |